All In Biotech

Drug Trial Radar · NCT07043751

A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors

A Phase I Clinical Trial Evaluating the Tolerance, Pharmacokinetics and Preliminary Efficacy of Injection TQB6411 in Subjects With Advanced Malignant Tumors

Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

216

Planned (sponsor's estimate)

Start

Jul 15, 2025

Primary completion

Dec 2027

Study completion Jun 2028

Sponsor

Sponsor type
Industry
First posted
Jun 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TQB6411 for injection is an antibody-conjugated drug (ADC) targeting EGFR/c-Met. After injecting blood intravenously, the antibody part of this product binds to the surface of EGFR and c-Met on tumor cells to block the activation of EGFR and c-Met signaling pathways. The ADC is enzymatically transported to the lysosome. The linker releases toxins after enzyme cleavage, resulting in DNA damage and cell death. TQB6411 for injection is intended for the treatment of advanced malignant tumors.

Conditions

  • Advanced Malignant Tumors

Interventions

  • TQB6411 injectionDrug

    TQB6411 for injection is an antibody-conjugated drug (ADC) targeting EGFR/c-Met. After injecting intravenously, the antibody part of this product binds to the EGFR and c-Met on the surface of tumor cells to block the activation of EGFR and c-Met signaling pathways. The ADC is enrolled and transported to the lysosome through cells. The linker releases toxins after enzyme cleavage, resulting in DNA damage and cell death.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicityTime frame: Up to24 months
  2. Maximum Tolerated DoseTime frame: Up to24 months
  3. Phase II recommended doseTime frame: Up to24 months
  4. Rate and severity of adverse eventsTime frame: Up to24 months

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Dongguan People's Hospital

    Dongguan, Guangdong, China · Not yet recruiting

  • ZhuJiang Hospital of Southern Medical University

    Guangdong, Guangdong, China · Not yet recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Not yet recruiting

  • Anyang Tumor Hospital

    Anyang, Henan, China · Not yet recruiting

  • The Henan Cancer Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • Zhongnan Hospital Of Wuhan University

    Wuhan, Hubei, China · Not yet recruiting

  • the Second Xiangya Hospital of Central South University

    Changsha, Hunan, China · Not yet recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China · Not yet recruiting

  • Jining First People's Hospital

    Jining, Shandong, China · Not yet recruiting

  • Shanghai Jiaotong University School of Medicine, Renji Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China · Not yet recruiting

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China · Not yet recruiting

  • Mianyang Central Hospital

    Mianyang, Sichuan, China · Not yet recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.